UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE
ISSUER
Pursuant
to Rule 13a-16 or 15d-16 of
The Securities Exchange Act of
1934
November 6,
2008
Teva Pharmaceutical Industries
Ltd.
(Exact name of registrant as specified in
its charter)
5 Basel Street, P.O. Box
3190
Petach Tikva 49131 Israel
(Address of
principal executive offices)
0-16174
(Commission File Number)
Indicate by check mark whether the registrant files or will
file
annual reports under cover of Form 20-F or Form 40-F:
Form 20-F / x /
Form 40-F / /
Indicate by check mark whether the registrant by furnishing
the
information contained in this form is also thereby furnishing the
information to the
Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes / /
No / x /
On November 6, 2008 the Registrant issued a press release, a
copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by
reference.
(c) Exhibit 99.1. Press release dated November
6, 2008
Pursuant to the requirements of the
Securities Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned thereunto duly authorized.
| |
|
Teva Pharmaceutical Industries
Limited
(Registrant)
|
November 6, 2008
(Date) |
|
/s/ DAN SUESSKIND
Dan Suesskind
Chief Financial Officer
|